Abstract
Human retinoblastoma binding protein 9 (RBBP9) is an interacting partner of the retinoblastoma susceptibility protein (Rb). RBBP9 is a tumor-associated protein required for pancreatic neoplasia, affects cell cycle control, and is involved in the TGF-β signalling pathway. Sequence analysis suggests that RBBP9 belongs to the α/β hydrolase superfamily of enzymes. The serine hydrolase activity of RBBP9 is required for development of pancreatic carcinomas in part by inhibiting TGF-β antiproliferative signaling through suppressing Smad2/3 phosphorylation. The crystal structure of human RBBP9 confirms the α/β hydrolase fold, with a six-stranded parallel β-sheet flanked by α helixes. The structure of RBBP9 resembles that of the YdeN protein from Bacillus subtilis, which is suggested to have carboxylesterase activity. RBBP9 contains a Ser75-His165-Asp138 catalytic triad, situated in a prominent pocket on the surface of the protein. The side chains of the LxCxE sequence motif that is important for interaction with Rb is mostly buried in the structure. Structure- function studies of RBBP9 suggest possible routes for novel cancer drug discovery programs.
Keywords: α/β hydrolase, pancreatic cancer, protein structure, structural genomics, RBBP9, antiproliferative, Smad2/3 phosphorylation, Bacillus subtilis, Ser75, emetine, E-cadherin
Protein & Peptide Letters
Title: Human Retinoblastoma Binding Protein 9, a Serine Hydrolase Implicated in Pancreatic Cancers
Volume: 19 Issue: 2
Author(s): Sergey M. Vorobiev, Yuanpeng Janet Huang, Jayaraman Seetharaman, Rong Xiao, Thomas B. Acton, Gaetano T. Montelione and Liang Tong
Affiliation:
Keywords: α/β hydrolase, pancreatic cancer, protein structure, structural genomics, RBBP9, antiproliferative, Smad2/3 phosphorylation, Bacillus subtilis, Ser75, emetine, E-cadherin
Abstract: Human retinoblastoma binding protein 9 (RBBP9) is an interacting partner of the retinoblastoma susceptibility protein (Rb). RBBP9 is a tumor-associated protein required for pancreatic neoplasia, affects cell cycle control, and is involved in the TGF-β signalling pathway. Sequence analysis suggests that RBBP9 belongs to the α/β hydrolase superfamily of enzymes. The serine hydrolase activity of RBBP9 is required for development of pancreatic carcinomas in part by inhibiting TGF-β antiproliferative signaling through suppressing Smad2/3 phosphorylation. The crystal structure of human RBBP9 confirms the α/β hydrolase fold, with a six-stranded parallel β-sheet flanked by α helixes. The structure of RBBP9 resembles that of the YdeN protein from Bacillus subtilis, which is suggested to have carboxylesterase activity. RBBP9 contains a Ser75-His165-Asp138 catalytic triad, situated in a prominent pocket on the surface of the protein. The side chains of the LxCxE sequence motif that is important for interaction with Rb is mostly buried in the structure. Structure- function studies of RBBP9 suggest possible routes for novel cancer drug discovery programs.
Export Options
About this article
Cite this article as:
M. Vorobiev Sergey, Janet Huang Yuanpeng, Seetharaman Jayaraman, Xiao Rong, B. Acton Thomas, T. Montelione Gaetano and Tong Liang, Human Retinoblastoma Binding Protein 9, a Serine Hydrolase Implicated in Pancreatic Cancers, Protein & Peptide Letters 2012; 19 (2) . https://dx.doi.org/10.2174/092986612799080356
DOI https://dx.doi.org/10.2174/092986612799080356 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atoh1: Landscape for Inner Ear Cell Regeneration
Current Gene Therapy Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery MDM4 (MDMX) and its Transcript Variants
Current Genomics Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets DNA Methylation and Breast Cancer
Current Genomics Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets The Effects of All-Trans-Retinoic Acid on Cell Cycle and Alkaline Phosphatase Activity in Pancreatic Cancer Cells
Medicinal Chemistry Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets
CNS & Neurological Disorders - Drug Targets Radiation-Induced Response of Micro RNA Expression in Murine Embryonic Stem Cells
Medicinal Chemistry Crosstalk between IGF Signaling and Steroid Hormone Receptors in Breast Cancer
Current Pharmaceutical Design MicroRNAs Determining Carcinogenesis by Regulating Oncogenes and Tumor Suppressor Genes During Cell Cycle
MicroRNA Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy